The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
On September 26, the U.S. Food and Drug Administration (FDA) approved a drug called Cobenfy to treat schizophrenia. Cobenfy is a combination of xanomeline and trospium chloride that has a novel ...
WASHINGTON/NEW YORK, Nov 15 (Reuters) - Robert F. Kennedy Jr. vowed to purge the U.S. Food and Drug Administration shortly before being chosen as President-elect Donald Trump's nominee for ...
However, in my estimation, starting in 2026, this financial metric will resume growth, including due to Cobenfy, which was ...
The Center for Science in the Public Interest, a watchdog group that has often clashed with the FDA, likened the pick to "putting a Flat Earther at the head of NASA." Marks, a career civil servant ...
In September, the FDA approved the first new schizophrenia treatment in decades. 1 Cobenfy (xanomeline and trospium chloride) has a new mechanism of action, and there is a lot of potential for ...
The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...
A new bill in Congress would compel the FDA to more aggressively police such promotions on social media platforms. “Some people become very attached to social media influencers and ascribe to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback